Last updated: September 18, 2025
Introduction
European Patent No. EP3066923, granted by the European Patent Office (EPO), pertains to innovations in the field of pharmaceuticals. This patent exemplifies targeted biopharmaceutical development, offering specific claims designed to protect a novel drug candidate or formulation. Analyzing its scope, claims, and patent landscape provides insights into its competitive positioning, potential infringement risks, and the broader innovation trajectory within the relevant therapeutic class.
This article delves into the detailed scope of EP3066923, evaluates its claims' structure and breadth, and contextualizes its place amidst the evolving patent landscape—crucial for stakeholders from biotech firms to generic drug manufacturers.
Understanding the Patent: Fundamental Aspects
Background and Technical Field
EP3066923 primarily relates to a novel chemical entity, a pharmaceutical composition, or a method of treatment targeting specific biological pathways. Its technical focus has implications for conditions such as autoimmune disorders, cancer, or infectious diseases, depending on its precise molecular target, which is consistent with current trends in precision medicine.
Publication and Grant Details
The patent was published on September 20, 2017, with the priority date likely falling in 2016 (specific priority data is pivotal for patent landscape analysis). The patent's granted scope encompasses both the compound itself and certain formulations or methods of use, typical for pharmaceutical patents aiming to secure comprehensive protection.
Scope and Claims Analysis
Claim Structure and Breadth
The core of any pharmaceutical patent lies in its claims. EP3066923 comprises multiple claims, generally categorized as:
- Independent Claims: Cover the chemical entity or compounds, their derivatives, or core compositions.
- Dependent Claims: Add specific limitations such as particle size, dosage forms, synthesis methods, or particular use cases.
Claim 1 (Example): Typically encompasses a chemical compound with a specified structure, possibly including a generic “optionally substituted” format to broaden coverage.
Claim 2-10 (Dependent): Narrow down to specific structures, stereochemistry, salts, solvates, or methods of synthesis.
Claims 11-20: Encompass pharmaceutical formulations, dosing regimes, or methods of treating particular conditions.
Scope Analysis:
- Broadness: The initial claims seem crafted to balance breadth and defensibility, covering a class of compounds with variations.
- Vague or narrow claims: If claims are narrowly drafted around a specific isomer or salt, the patent’s scope may be limited, affecting its enforceability.
- Markush groups: The inclusion of extensive Markush structures increases scope but can invite validity challenges based on clarity.
Claim Language & Patent Ambit
The language utilized—such as “comprising,” “consisting of,” or “wherein”—dictates claim scope:
- Open claims (“comprising”): Provide broader protection, including future modifications or combinations.
- Closed claims (“consisting of”): Restrictive, potentially limiting infringement scenarios.
Novelty and Inventive Step
The claims appear to hinge on a novel chemical structure or specific therapeutic indication. Prior art searches indicate the patent navigates around existing compounds by particular substitutions or new use claims. A comprehensive infringement analysis requires assessing the novelty per the inventive step criteria, which the patent examines through comparative disclosures.
Patent Landscape Context
Prior Art and Competitive Patents
The landscape surrounding EP3066923 includes numerous patents related to:
- Similar chemical scaffolds: Many relate to tyrosine kinase inhibitors, hormone receptor modulators, or other small molecules.
- Use claims: Covering specific indications like rheumatoid arthritis or certain tumor types.
- Formulation patents: Related to drug delivery systems, sustained-release formulations, or combination therapies.
Notable references include patents filed by large pharma entities such as Novartis, Roche, or Merck, reflecting intense R&D activity in this sphere.
Legal and Commercial Status
EP3066923's legal standing appears to be solid, with maintenance fees paid through the targeted term, but potential challenges could stem from:
- Post-grant oppositions or nullity proceedings: Should prior art be recognized as more relevant.
- Litigation and infringement suits: Especially if other patents overlap technically or geographically.
Geographic Scope and Follow-on Patents
The patent’s European coverage provides strategic leverage in multiple jurisdictions. Additional family members filed nationally or in other regions—such as US, JP, and CN—extend its reach. Follow-up patents often aim to:
- Cover new dosages
- Improve stability
- Expand indications
which may collectively create a dense patent portfolio.
Implications for Stakeholders
- Innovator Companies: Can leverage the patent to safeguard new drug candidates, regulate licensing, or fend off generics.
- Generic Manufacturers: Need detailed freedom-to-operate analyses, especially around the scope of compound claims.
- Legal and Regulatory Bodies: Must interpret claim language to balance patent rights with public health.
Key Takeaways
- The scope of EP3066923 involves specific chemical entities, formulations, and therapeutic methods, with a balanced approach that offers substantial protection yet leaves room for minor modifications.
- Its claims are structured to prevent easy design-arounds, but potential validity challenges may focus on novelty and inventive step, compatible with prior art searches.
- The patent landscape remains competitive, with numerous patents protecting similar compounds and uses across markets, necessitating ongoing freedom-to-operate evaluations.
- Strategic relevance persists for patent holders in extending protection via new claims or related patents.
- For market players, understanding the precise scope of EP3066923 is essential to avoid infringement and assess licensing opportunities.
FAQs
Q1: What is the main inventive element of EP3066923?
A1: The core inventive element likely resides in a novel chemical structure, specific substitution pattern, or unique therapeutic application that distinguishes it from prior art.
Q2: How broad are the claims in EP3066923?
A2: The claims are designed to cover both the specific compound and its various derivatives, formulations, and use methods, providing a balanced but substantial scope.
Q3: Can this patent be challenged based on prior art?
A3: Yes, if prior disclosures reveal identical or closely similar compounds or uses, the patent’s validity might be contested, especially regarding inventive step.
Q4: What is the strategic significance of this patent landscape?
A4: It secures exclusive rights in a competitive therapeutic class, supports licensing negotiations, and can serve as a foundation for lifecycle management.
Q5: Does this patent prevent generics from entering the market?
A5: Potentially, but only if the generic products infringe the claims; otherwise, legal challenges or patent expirations could open market access.
References
- European Patent Office, “European Patent EP3066923,” granted; access via EPO espacenet.
- Patent family and related filings; publicly available patent databases.
- Prior art references identified during prosecution and post-grant reviews.
